Immix Biopharma (IMMX) EBT (2021 - 2026)

Immix Biopharma has reported EBT for 6 years, with the latest figure at -$10.1 million in Q1 2026.

• Quarterly EBT fell 122.53% year-over-year to -$10.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$35.0 million (down 4542.14% YoY) and the FY2025 annual result came in at -$29.4 million, down 1806.04% from the prior year.
• EBT rose to -$10.1 million in Q1 2026 per IMMX's latest filing, from -$10.7 million in the prior quarter.
• Over five years, EBT peaked at $15.3 million in Q4 2024 and troughed at -$10.7 million in Q4 2025.
• A 5-year average of -$3.8 million and a median of -$4.4 million in 2024 frame the typical range for EBT.
• The sharpest annual moves came in 2022 and 2024: EBT tumbled 654.03% in 2022, then jumped 397.51% in 2024.
• Over 5 years, EBT stood at -$3.8 million in 2022, then tumbled by 35.65% to -$5.1 million in 2023, then surged by 397.51% to $15.3 million in 2024, then plunged by 169.72% to -$10.7 million in 2025, then rose by 5.52% to -$10.1 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$10.1 million, -$10.7 million, and -$7.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.